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Abstract
Background: After more than a decade of community-directed treatment with ivermectin (CDTI) in Centre and
Littoral Regions of Cameroon, onchocerciasis endemicity was still high in some communities according to the 2011
epidemiological evaluations. Some corrective measures were undertaken to improve the CDTI process and
therefore reduce the burden of the disease. The objective of the present study was to assess the progress made
towards the elimination of onchocerciasis in the Centre 1 and Littoral 2 CDTI projects where the worst
performances were found in 2011. To this end, a cross-sectional survey was conducted in April 2015 in eight
communities in two health districts (HD), Bafia in Centre 1 and Yabassi in Littoral 2, chosen because assessed at
baseline and in 2011. All volunteers living for at least five years in the community, aged five years or more,
underwent clinical and parasitological examinations. Individual compliance to ivermectin treatment was also
assessed. Analyses of data were weighted proportionally to age and gender distribution in the population.
Results: In the Bafia and Yabassi HD, 514 and 242 individuals were examined with a mean age of 35.1 (standard
deviation, SD: 20.7) and 44.6 (SD: 16.3) years, respectively. In the Bafia HD, the weighted prevalences varied from 24.4 to
57.0 % for microfilaridermia and from 3.6 to 37.4 % for nodule presence across the surveyed communities. The
community microfilarial load (CMFL), expressed in microfilariae/skin snip (mf/ss), significantly dropped from 20.84–114.
50 mf/ss in 1991 to 0.31–1.62 mf/ss in 2015 in all the surveyed communities. In the Yabassi HD, the weighted
prevalences varied from 12.3 to 59.3 % for microfilaridermia and from 1.5 to 3.7 % for nodule presence across the
surveyed communities, while a significant drop was observed in CMFL, from 20.40–28.50 mf/ss in 1999 to 0.48–1.74
mf/ss in 2015. The 2014 weighted therapeutic coverage of participants varied from 65.8 % (95 % CI: 58.4–73.2) in
Yabassi HD, to 68.0 % (95 % CI: 63.3–72.7) in Bafia HD, with important variations among communities.
Conclusions: After more than 15 years of CDTI, onchocerciasis is still mesoendemic in the surveyed communities.
Further studies targeting therapeutic coverage, socio-anthropological considerations of CDTI implementation and
entomological studies would bring more insights to the persistence of the disease as observed in the present study.
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Background
Onchocerciasis, better known as river blindness, is a
debilitating insect-borne parasitic disease caused by
Onchocerca volvulus and transmitted via the bites of
blackflies of the genus Simulium. The larvae and pupae
of the latter develop in fast-flowing and well-oxygenated
streams and rivers. The prevalence of infection and
disease in a community is therefore related to riverine
breeding sites of the vector. The disease is endemic in
30 African countries, in Yemen and in localized foci in
four Latin American countries. About 120 million
people are at risk worldwide, with 99 % of them living in
Africa, and 37 million were infected in 1995, when the
African Programme for Onchocerciasis Control (APOC)
was launched [1, 2].
Adult O. volvulus average lifespan is estimated to 10–15
years [3, 4]. Individual female worms produce daily thou-
sands of microfilariae whose lifespan varies from 12 to 18
months. By invading the host dermis and eyes, live micro-
filariae interact with the host immune system, while dead
microfilariae induce inflammatory responses, causing a
variety of skin and ocular symptoms [5–7]. Infection leads
to severe skin damage with unrelenting itching, visual
impairment and blindness. Irreversible onchocercal blind-
ness is ranked as the world’s second leading infectious
cause of preventable blindness after trachoma [8]. Besides
its clinical impact, river blindness also has an important
socio-economic impact on affected populations. It cre-
ates stigma [9] and generates and perpetuates poverty.
Fear of the disease often prompted people to abandon
fertile lands which in turn led to an increase in poverty
and famine, making the disease a major obstacle to
socioeconomic development. The agricultural product-
ivity is therefore hindered, generating massive eco-
nomic losses and imposing a disproportionate disease
burden in poor rural communities [10].
Ivermectin is currently the only known effective and
safe drug used for mass treatments against onchocercia-
sis. However, since this drug has a limited macrofilarici-
dal activity, treatments must be repeated for more than
15 years. The control of onchocerciasis has been quite
successful with the implementation of Community
Directed Treatment with Ivermectin (CDTI). This strat-
egy, proposed by the World Health Organization
(WHO) through APOC, has significantly improved
Ivermectin treatment coverage [11–13]. While this drug
has been administrated twice or four times a year in the
small and well-delineated endemic communities of the
Americas, single doses have been given yearly in the
much larger foci in African endemic countries [14, 15].
As a consequence, the programmes in the Americas are
highly successful and are attaining the onchocerciasis
elimination point [16–20], while this disease remains a
public health problem in Africa. Nevertheless, new
evidence points exist towards the possibility of successful
elimination of river blindness in Africa using ivermectin
solely [21, 22]. Indeed, a spectacular decrease in microfi-
laridermia prevalence below 1 % was reported in Mali
and Senegal [22], as well as in some CDTI-project in the
APOC countries [23, 24]. However, despite more than
20 years of disease control, onchocerciasis remains a
major concern for several endemic countries, including
Cameroon [25]. Indeed, recent WHO/APOC surveys
conducted in 2011 revealed onchocerciasis prevalences
above 60 % in the Centre 1, Littoral 2 and West CDTI-
projects in Cameroon [24]. The reasons for the persistence
of the infection are yet to be elucidated, and it is not clear
whether this is due to low treatment coverage, systematic
non-compliance of a proportion of the population, or sub-
optimal response of the parasite to ivermectin [26–28].
These poor results led to the implementation of some cor-
rective measures (frequent and regular supportive supervi-
sion, data quality audit, community self-monitoring and a
better drug management) by the National Onchocerciasis
Control Programme to improve the CDTI performances.
The objective of the present survey was, therefore, to
assess the progress made towards the elimination of
onchocerciasis in the Centre 1 and Littoral 2 CDTI pro-
jects where the worst performances were found in 2011.
Methods
Study area and selection of communities
The present study was conducted in the Bafia (4°45′00″
N, 11°14′00″E) and Yabassi (4°27′16″N, 9°57′56″E)
health districts (HD), belonging to the Centre 1 and
Littoral 2 CDTI projects, respectively.
The Bafia HD is located in the Mbam and Inoubou
Division (Centre Region), at 120 km north from
Yaoundé, the political capital of Cameroon. In 2014, its
population was 226,073 inhabitants, based on a census
conducted by community-directed distributors (CDD).
The altitude of this region varies from 1,100 to 1,300 m.
It is a forest-savanna transition zone, irrigated by many
fast-flowing rivers including Sanaga and its tributaries,
as well as the Mbam and Noun rivers. The main activ-
ities of inhabitants are agriculture (mainly cocoa), fishing
and sand mining.
The Yabassi HD is located in the Nkam Division
(Littoral Region), at 100 km north-east from Douala, the
economic capital of the country. According to the 2014
CDD census, its population was 21,459 inhabitants. The
relief is undulating, showing an alternation of valleys
and plains. Altitude of the region varies from 10 to 800
m. This district is irrigated by many fast-flowing rivers
comprising Nkam, Dibamba, Mabombé, Njanga and
Mahé which are favorable to blackfly breeding. The
vegetation is mainly dense humid forest. Agriculture is
the main activity, interesting at least 60 % of inhabitants.
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Baseline and follow-up surveys
Surveyed communities were selected according to the
availability of baseline data and the results of the 2011
follow-up survey carried out by the National Onchocer-
ciasis Control Programme (NOCP) with the support of
APOC (NOCP, unpublished report). The prevalence and
intensity of infection (nodules and microfilaridermia)
had also been assessed in 1991–1993 by an IRD-Centre
Pasteur du Cameroun team in seven communities of the
Bafia HD [29], and in 1999 in seven communities of the
Yabassi HD (Kamgno, unpublished report). From these
14 communities, four (Balamba II, Biatsota, Ngongol
and Tsékané) in the Bafia HD and four (Bodiman, Bona-
dissake, Ndogpoo and Nkongmalan) in the Yabassi HD,
with the highest microfilaridermia prevalence and/or
community microfilarial load (CMFL), were selected for
the present survey (Tables 1 and 2; Fig. 1).
History of mass treatment with ivermectin
In the Bafia HD, a clinical trial was conducted between
1994 and 1998, with mass treatment carried out in some
communities [30, 31]. However, according to the NOCP,
CDTI started in 1999 and in 2000 in Littoral 2 and
Centre 1 projects, respectively [32]. So these communi-
ties received 16 rounds and 15 rounds of mass drug ad-
ministration, respectively. The therapeutic coverage
achieved in each project is illustrated in Fig. 2. Even
though the two projects achieved the treatment coverage
threshold for control (65 %) during the last 13 years,
none of them reached 80 % treatment coverage, the
threshold for elimination, although a significant im-
provement has been achieved since 2012.
Study design and patients
A cross-sectional survey was conducted in April 2015 in
eight communities of the Bafia and Yabassi health dis-
tricts, nine months after the previous annual ivermectin
distribution. All individuals, permanent residents or who
had already lived for at least five years in the community
and aged five years or more were eligible for this survey.
All volunteers underwent clinical and parasitological
examinations. In addition, individual compliance to iver-
mectin treatment was also assessed.
Clinical examination
Each participant was examined for skin disease and
nodules. The searched cutaneous signs were depigmen-
tation, onchodermatitis (acute, chronic and lichenified),
hanging groin and skin atrophy. Participants were
scored as ‘positive’ or ‘negative’ to each cutaneous sign.
Nodule palpation was performed in a closed but well-
illuminated room. Qualified and certified staff per-
formed the palpation on partially disrobed participants
while paying particular attention to bony prominences
of the torso, iliac crests and upper trochanter of the
femurs. Onchocercal nodules were identified clinically
as mobile masses beneath the skin, firm and painless
[33–35]. Results were ranked as ‘positive’ or ‘negative’,
and if positive, the number and location of all palpable
onchocercal nodules were recorded.
Parasitological examination
Immediately following the nodule palpation, two skin
snips were taken from each posterior iliac crest using a 2
mm corneoscleral punch (Holth-type). The skin samples
were immediately placed, separately, into wells of microti-
tration plates containing a sterile normal saline solution.
After 24 h incubation at room temperature, the skin snips
were removed and the fluid from each well was examined
under low magnification (40×) by trained laboratory tech-
nicians [36]. For positive results, the microfilariae were
counted and the individual microfilarial densities were
expressed as the arithmetic mean number of microfilariae
in the two skin snips (mf/ss).
Assessment of the individual compliance to ivermectin
mass treatment
Individual compliance to ivermectin mass treatment
was assessed by asking each participant if he/she swal-
lowed ivermectin tablets during each of the previous
five years (including the last CDTI-campaign). Iver-
mectin tablets were presented to the participants to
make sure that the interview was targeting the right
Table 1 Onchocerciasis burden in four communities of Bafia
health district at baseline and during the 2011 survey, after 11
years of CDTI









Tsékané 150 90.8 20.84 204 47.1 1.44
Balamba II 167 83.7 26.40 212 61.0 4.72
Ngongol I 129 92.8 90.31 237 64.0 2.54
Biatsota 150 94.0 114.50 227 67.6 3.26
Abbreviations: N number examined, mf microfilaria, CMFL community
microfilarial load (microfilariae/skin snip)
Table 2 Onchocerciasis burden in four communities of Yabassi
health district at baseline and during the 2011 survey









Bonadissake 58 79.3 20.4
Ndogpoo 39 87.2 24.2
Nkongmalan 84 92.2 28.5
Bodiman 81 90.1 26.5 112 65.2 2.96
Abbreviations: N number examined, mf microfilaria, CMFL community
microfilarial load (microfilariae/skin snip)
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treatment. The participant answers were recorded on
an individual form as “yes” or “no” for each of the last
five years.
Data analysis
All relevant data (clinical signs, nodule, mf count, and
compliance to ivermectin mass treatment) were recorded
into a purpose-built Microsoft Access database and subse-
quently exported into STATA 13 for statistical analysis.
All analyses were weighted proportionally to age- and
gender distribution in the population, according to 2015
national demographic data projections [37]. Cutaneous
signs, nodules and microfilaridermia prevalences were
expressed as the proportion of infected or affected individ-
uals with the 95 % exact confidence interval (CI). Each
community was classified according to the prevalence of
microfilaridermia as hypoendemic (prevalence ˂ 35 %),
mesoendemic (35 % ≤ prevalence ˂ 60 %) or hyperen-
demic (prevalence ≥ 60 %) [38]. When the microfilarial
count was positive, the intensity of infection was
computed as the arithmetic mean and its 95 % CI. The
community microfilarial load (CMFL), defined as the
Fig. 1 Map of Cameroon showing the study areas and communities surveyed
Fig. 2 Therapeutic coverage in Centre 1 and Littoral 2 CDTI projects
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geometric mean number of microfilariae per skin snip
among adults aged 20 years or more, was calculated using




where x is the individual microfilarial density, and N the
total number of individuals aged 20 years and above.
Proportions were compared using Chi-square tests.
Mean intensities of infection were compared between
age- and gender subgroups using ANOVA with F-tests
or t-tests. A P-value < 0.05 was considered as statistically
significant.
Results
In the two HD, 514 and 242 individuals were examined.
Mean ages were 35.1 (SD: 20.7) and 44.6 (SD: 16.3)
years, respectively. The sex ratio was slightly female-
biased in the Bafia HD (female proportion of 51.8 %),
but was male-biased in the Yabassi HD (female propor-
tion equal to 45.9 %).
Prevalence and intensity of infection
In Bafia HD, weighted prevalences varied from 24.4 to
57.0 % for microfilaridermia and 3.6 to 37.4 % for nodule
prevalence across the surveyed communities. Men were
more affected than women, both for microfilaridermia
(47.5 vs 36.5 %; χ2 = 6.4, df = 1, P = 0.03) and nodule
presence (27.1 vs 10.5 %; χ2 =23.8, df = 1, P < 0.001).
The communities Biatsota and Ngongol I had the high-
est burden, both for microfilaridermia and nodule preva-
lence, and were ranked as mesoendemic according to the
microfilaridermia prevalence. Balamba II and Tsékané
were ranked as hypoendemic although still presenting
with high prevalences after 15 years of treatment (Table 3).
Across age groups, no significant differences in microfilari-
dermia prevalence were observed, while nodule prevalence
increased with age. Arithmetic mean of microfilaridermia
among positive cases was higher in younger participants
(9–19 years) and decreased with age, thus displaying an
opposite trend to the one observed for nodule prevalence
(Table 4).
A significant reduction in prevalence was observed in
all communities when comparing the present data to
baseline data (χ2 = 222.6, df = 9, P < 0.001) (Fig. 3). The
CMFL in all the surveyed communities also significantly
dropped by 98-99 % from 20.84–114.50 mf/ss in
1991 to 0.31–1.62 mf/ss in 2015 (ANOVA: F(1,3) =
131.6, P < 0.001) (Fig. 4).
In Yabassi HD, weighted prevalences varied from 12.3
to 59.3 % for microfilaridermia and from 1.5 to 3.7 % for
nodules. Men were more affected than women, both for
microfilaridermia (48.7 vs 38.4 %; χ2 =2.6, df = 1, P =
0.17) and nodule presence (4.5 vs 0.7 %; χ2 =3.3, df = 1,
P = 0.07); however, the differences were not statistically
significant. Onchocercal skin lesions were more frequent
in two communities (Bonadissake and Ndogpoo) where
lower limb depigmentation, acute and chronic onchoder-
matitis were found (Table 3). The arithmetic mean of
microfilarial load decreased with age while the mean
number of nodules increased (Table 4).
A significant reduction in prevalence was found in all
communities when comparing baseline to the follow-up
data in 2015 (χ2 = 107.6, df = 9, P < 0.001) (Fig. 5). A
significant drop in CMFL by 94–98 %, was also ob-
served, from 20.40–28.50 in 1999 to 0.48–1.74 mf/ss in
2015 (ANOVA: F(1,3) = 1554.7, P < 0.001) (Fig. 6). Most
palpable nodules were localized in the pelvic grid, the
back, the chest and the knee with half of them found in
the pelvic grid (Fig. 7).
Table 3 Parasitological load and clinical signs of onchocerciasis within each community in the present survey of 2015
District and community Microfilaridermia examination Clinical examination weighted prevalence (%)
N Weighted prevalence (%) CMFL (mf/ss) Status Nodule Cutaneous sign
Bafia
Balamba II 138 24.4 0.51 Hypoendemic 3.6 1.1
Biatsota 94 45.8 1.04 Mesoendemic 37.4 7.0
Ngongol I 186 57.0 1.62 Mesoendemic 23.9 1.5
Tsékané 96 26.4 0.31 Hypoendemic 7.2 3.0
Total 514 41.6 Mesoendemic 18.1 2.3
Yabassi
Bodiman 64 59.3 1.39 Mesoendemic 3.7 2.8
Bonadissake 41 12.3 0.48 Hypoendemic 1.6 22.4
Ndogpoo 80 46.7 1.10 Mesoendemic 1.5 10.9
Nkongmalan 57 47.7 1.74 Mesoendemic 3.5 4.6
Total 242 43.8 Mesoendemic 2.7 9.3
Abbreviations: N number examined, mf microfilaria, CMFL community microfilarial load (microfilariae/skin snip)
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Compliance to ivermectin mass treatments in surveyed
communities
The weighted therapeutic coverage in 2014 varied from
65.8 % (95 % CI: 58.4–73.2) to 68.0 % (95 % CI: 63.3–72.7)
in the surveyed communities from Yabassi HD and Bafia
HD, respectively, with important variations across com-
munities. A variation was also observed in the compliance
to ivermectin over five years, from 39.9 % (95 % CI: 35.2–
44.6) in Bafia HD to 54.0 % (95 % CI: 46.6–61.4) in Yabassi
HD. The adherence to treatment increased significantly
with age since more than 75 % of participants aged 40
years and above declared having taken the treatment
each year during the last five years, whereas only 31 %
of individuals aged 10–29 years did so (χ2 = 234.6, df =
Table 4 Microfilaria and nodule status across age groups in the present survey of 2015
District Age categories
(years)
Microfilaria status Nodule status
N Mf+ (n) Weighted
prevalence (%)a
Weighted mean ± SD
of mf in carriers
Nod+ (n) Weighted
prevalence (%)a
Weighted mean ± SD
of nodules in carriers
Bafia 5–9 56 19 34.0 20.5 ± 27.7 9 16.1 1.7 ± 0.7
10–19 94 47 50.0 24.9 ± 47.6 9 9.6 2.2 ± 1.4
20–29 76 32 41.5 10.9 ± 22.4 12 14.9 2.1 ± 1.1
30–39 70 28 40.0 13.8 ± 24.0 23 32.5 2.6 ± 2.1
40–49 69 24 34.7 13.5 ± 24.6 21 30.4 2.6 ± 2.3
50–59 70 26 37.2 6.6 ± 9.3 17 24.5 2.8 ± 2.0
60+ 79 20 25.4 7.6 ± 12.5 24 30.0 2.5 ± 2.6
Total 514 196 41.6 17.9 ± 35.5 115 18.1 2.4 ± 1.8
Yabassi 5–9 0 – – – – – –
10–19 14 7 50.0 21.4 ± 21.3 0 0 0
20–29 35 13 36.6 16.5 ± 29.3 0 0 0
30–39 47 23 48.9 16.1 ± 26.5 1 2.1 1
40–49 48 17 35.4 5.1 ± 6.9 3 6.3 1.7 ± 0.6
50–59 51 28 54.9 11.2 ± 19.4 4 8.0 2 ± 0.8
60+ 47 21 44.7 7.3 ± 12.5 2 4.1 2.5 ± 0.7
Total 242 109 43.8 14.2 ± 22.6 10 2.7 1.8 ± 0.7
Abbreviations: N number examined, mf microfilaria, Mf+ (n) number with microfilaria positive skin snip, Nod+ (n) number of nodule carriers, SD standard deviation
aIn each age category, the indices were adjusted on sex; in the total populations, indices were adjusted on sex and age
Fig. 3 Comparison of weighted microfilaridermia prevalences at baseline, 1991, with follow-up surveys in 2011 and 2015, in the communities sur-
veyed in the Bafia health district
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30, P < 0.001). More than one out of five participants in
Bafia HD (21.3 %; 95 % CI: 17.1–25.5) and Yabassi HD
(22.0 %; 95 % CI: 15.3–28.6) declared that they had not
taken the treatment during the last five years (Figs. 8 and
9). The microfilaridermia prevalence was associated with
treatment compliance in Bafia HD (χ2 = 14.0, df = 5, P=
0.016), but not in Yabassi HD (χ2 = 10.5, df = 5, P =
0.062), whereas its intensity was significantly negatively
associated with compliance to treatment in both districts
(ANOVA: F(5, 299) = 5.95, P < 0.001) as shown in Fig. 10.
Discussion
The objective of this study was to assess the progress
made towards the elimination of onchocerciasis in the
Fig. 4 Comparison of community microfilarial load at baseline, 1991, with follow-up surveys in 2011 and 2015, in the communities surveyed in
the Bafia health district. Abbreviations: mf, microfilaria; ss, skin snip
Fig. 5 Comparison of weighted microfilaridermia prevalences at baseline, 1999, with follow-up surveys in 2015, in the communities surveyed in
the Yabassi health district
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Centre 1 and Littoral 2 CDTI projects where high preva-
lence and intensity of infection were found in 2011. In
2015, after more than 15 years of mass treatment, we
observed a reduction in microfilaridermia prevalence,
but values were still above the expected level (≤ 20 % for
a pretreatment endemicity ≥ 80 % assuming a thera-
peutic coverage of 65 %) [39, 40]. Indeed, onchocerciasis
is still mesoendemic in many surveyed communities es-
pecially in those closest to fast-flowing rivers. Blackfly
breeding sites located a few kilometres from Biatsota,
Ngongol I and Bodiman contribute to maintain high
vector densities and continuing transmission as was pre-
viously demonstrated for first-line communities [29].
The same communities had the highest prevalences of
nodules in the two health districts. Furthermore, the
high microfilaridermia and nodule prevalences observed
in less than 10-year-old children, born after the launch
of the programme, are a strong evidence of ongoing
active transmission which could later be confirmed by
entomological studies. In addition to the parasite bur-
den, the persistence of the disease can also be explained
by the low adherence to treatment as only 40 and 54 %
Fig. 6 Comparison of community microfilarial load at baseline, 1999, with follow-up surveys in 2015, in the communities surveyed in the Yabassi
health district. Abbreviations: mf, microfilaria; ss, skin snip
Fig. 7 Distribution of nodules according to the anatomical localization in carriers
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of participants in Bafia HD and Yabassi HD, respectively,
declared having taken five treatments during the last five
years. At the same time, about 20 % of the participants
had taken no treatment during that period. With the
observed treatment coverage, the likelihood for the
programme to achieve elimination of the disease by
2025 is quite low. Even though this survey was con-
ducted nine months after the previous treatment, we
believe that our results regarding the therapeutic cover-
age and the compliance are reliable because ivermectin
tablets are special, by both their physical presentation
(small and white) and their delivery strategy. So, the
likelihood to confuse them with other drugs or interven-
tions is quite low. Previous studies have reported accur-
ate recall of populations when compared to the data
from CDTI collected in treatment registry [41–43].
Despite the high mf prevalences observed in both dis-
tricts, the intensity of infection had dramatically decreased
in 2015, with CMFL below 2 mf/ss in all communities, as
compared to baseline data. Even when compared to 2011,
the CMFL dropped by half in almost all surveyed commu-
nities. Furthermore, the arithmetic mean number of
microfilariae per skin snip among positive cases was found
to be related to compliance to treatment. Thus it could be
Fig. 8 Proportion of participants according to ivermectin treatment in the Bafia health district
Fig. 9 Proportion of participants according to ivermectin treatment in the Yabassi health district
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hypothesized that ivermectin would enable to eliminate
onchocerciasis in the study areas if CDTI were prop-
erly implemented as demonstrated in Mali and Nigeria
[44, 45]. An improvement in therapeutic coverage is a
major requirement in these areas with high baseline
intensities of infection.
As observed in previous studies, males were more af-
fected than females probably due to their socioeconomic
activities [46–48]. In addition, due to their prolonged
exposition to the bites of blackflies, the oldest partici-
pants have more nodules than their youngest counter-
parts; meanwhile their adherence to treatment could
explain their lowest intensity of infection. This adher-
ence is probably motivated by their awareness about the
consequences of the disease.
The localization of nodules was comparable to previous
studies [33–35, 49], especially in Biatsota and Ngongol I.
Onchocercal skin disease was more frequent in two
communities (Bonadissake and Ndogpoo) where lower
limb depigmentation, acute and chronic onchoderma-
titis were found.
Conclusions
After more than 15 years of CDTI, onchocerciasis is
still mesoendemic in the communities surveyed as
part of this study. Additional efforts should be made
to improve the CDTI therapeutic coverage in all com-
munities so as to greatly reduce the prevalence and
the microfilarial densities in order to eliminate this
debilitating disease in these two CDTI-projects. Fur-
ther studies targeting community therapeutic cover-
age, CDTI process and entomological studies would
provide better insights into our understanding of the
persistence of the disease as described in this study.
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